- NVAX, +30.80% as it rallied after the biotech announced it received a large 384m investment for its COVID-19 vaccine candidate and beat Earnings expectations.
- Technically we are in a strong uptrend - just broken out of its corrective move down. This is the type of stock which may take off further quite quickly - we could wait for a pullback (possibly at the old highs) or buy this breakout at the open market. Will depend on your risk appetite.
- Targets have been set based on the Pitchforks and Median Line Theory.